| dbo:abstract |
Molidustat ist ein , der die Produktion von Hämoglobin und Erythrozyten stimuliert. Es wurde im Januar 2021 in Japan unter dem Namen Musredo (Bayer Yakuhin) zugelassen zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CDK). (de) Molidustat (INN; Bay 85-3934) is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs. (en) |
| dbo:casNumber |
1154028-82-6 |
| dbo:fdaUniiCode |
9JH486CZ13 |
| dbo:kegg |
D12122 |
| dbo:pubchem |
59603622 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Molidustat_structure.png?width=300 |
| dbo:wikiPageID |
55985962 (xsd:integer) |
| dbo:wikiPageLength |
3026 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1115231097 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbc:Pyrazolones dbr:Desidustat dbc:Triazoles dbr:Anemia dbr:Performance-enhancing_drugs dbr:HIF_prolyl-hydroxylase_inhibitor dbr:Daprodustat dbr:Erythropoietin dbr:Chronic_kidney_disease dbr:Red_blood_cell dbc:Morpholines dbc:Pyrimidines dbr:Hemoglobin dbr:Roxadustat dbr:Vadadustat dbr:Athletic_doping |
| dbp:atcPrefix |
None (en) |
| dbp:c |
13 (xsd:integer) |
| dbp:casNumber |
1154028 (xsd:integer) |
| dbp:h |
14 (xsd:integer) |
| dbp:iupacName |
2 (xsd:integer) |
| dbp:kegg |
D12122 (en) |
| dbp:n |
8 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
59603622 (xsd:integer) |
| dbp:smiles |
C1COCCN1C2=NC=NCN3CCN4C=CN=N4 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
IJMBOKOTALXLKS-UHFFFAOYSA-N (en) |
| dbp:synonyms |
Bay 85-3934 (en) |
| dbp:unii |
9 (xsd:integer) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Abbrlink dbt:Blood-drug-stub |
| dcterms:subject |
dbc:Pyrazolones dbc:Triazoles dbc:Morpholines dbc:Pyrimidines |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Molidustat ist ein , der die Produktion von Hämoglobin und Erythrozyten stimuliert. Es wurde im Januar 2021 in Japan unter dem Namen Musredo (Bayer Yakuhin) zugelassen zur oralen Behandlung der Anämie („Blutarmut“) infolge einer chronischen Nierenerkrankung (CDK). (de) Molidustat (INN; Bay 85-3934) is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs. (en) |
| rdfs:label |
Molidustat (de) Molidustat (en) |
| owl:sameAs |
wikidata:Molidustat dbpedia-de:Molidustat https://global.dbpedia.org/id/2XsXc |
| prov:wasDerivedFrom |
wikipedia-en:Molidustat?oldid=1115231097&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Molidustat_structure.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Molidustat |
| is dbo:wikiPageRedirects of |
dbr:Molidustat_sodium |
| is dbo:wikiPageWikiLink of |
dbr:List_of_doping_cases_in_cycling dbr:Hypoxia-inducible_factor dbr:Matija_Kvasina dbr:HIF_prolyl-hydroxylase_inhibitor dbr:Daprodustat dbr:Team_Felbermayr–Simplon_Wels dbr:Vadadustat dbr:Molidustat_sodium |
| is foaf:primaryTopic of |
wikipedia-en:Molidustat |
